# Bayer

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/bayer/

## Facts

| Field | Value |
| --- | --- |
| Country | DE |
| Description | German multinational pharmaceutical, chemical, and agricultural biotechnology company |
| OpenAlex ID | https://openalex.org/F4320307771 |
| ROR ID | https://ror.org/04hmn8g73 |
| Works | 10,361 |

## Funder papers

Showing 15 of 39.

- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial](https://scholariq.org/papers/finerenone-reduces-risk-of-incident-heart-failure-in-patients-with-chronic/)
- [Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes](https://scholariq.org/papers/finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-2-diabetes/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes](https://scholariq.org/papers/finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes-fine/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <scp>FIDELIO‐DKD</scp> trial](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-with-and/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes](https://scholariq.org/papers/finerenone-and-heart-failure-outcomes-by-kidney-function-albuminuria-in-chronic/)
- [Finerenone and Kidney Outcomes in Patients With Heart Failure](https://scholariq.org/papers/finerenone-and-kidney-outcomes-in-patients-with-heart-failure/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery](https://scholariq.org/papers/levosimendan-in-patients-with-reduced-left-ventricular-function-undergoing/)
- [Combined versus Sequential Phacoemulsification and Pars Plana Vitrectomy](https://scholariq.org/papers/combined-versus-sequential-phacoemulsification-and-pars-plana-vitrectomy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.